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Tissue engineering applications to vascular bypass
graft development: The use of adipose-derived
stem cells
Paul DiMuzio, MD,a,b and Thomas Tulenko, PhD,b Philadelphia, Pa
The burgeoning field of vascular tissue engineering holds promise for the creation of a practical and successful
small-diameter arterial bypass graft. Many creative combinations of autologous cells and scaffolds exist along with an
equally long list of microenvironmental cues used to create a functional arterial conduit. This review outlines our work
using abdominal wall fat as a source of autologous stem cells for vascular tissue engineering, focusing specifically on this
stem cell’s availability and potency to differentiate into endothelial-like cells. In a series of 49 patients undergoing elective
peripheral vascular surgery, an abundant quantity of adult stem cells was harvested from fat obtained by liposuction. The
efficacy of the isolation did not appear influenced by advanced age, obesity, renal failure, or vascular disease, although fat
from diabetic patients yielded significantly less stem cells. In addition, these adipose-derived stem cells acquired several
morphologic and molecular endothelial phenotypes when exposed to growth factors (endothelial cell growth supplement
and vascular endothelial growth factor) and physiologic shear stress in vitro. Taken together, these studies suggest that
fat appears to be a viable source of autologous stem cells for use in vascular tissue engineering. (J Vasc Surg 2007;45:
99A-103A.)Vascular therapies are rapidly evolving, with a major
emphasis on the endovascular approach to arterial disease.
Despite this important trend, bypass of occluded arteries
remains an important technique in the treatment of periph-
eral and cardiovascular disease. It is well known that the
gold standard conduit for these procedures is autologous
vascular tissue such as great saphenous vein and internal
mammary and radial artery. In the absence of suitable
autologous tissues, alternative conduits such as nonabsorb-
able prosthetic grafts and cryopreserved vascular allografts
are used, but with significantly inferior results when used
for small-diameter artery bypass.
Tissue engineering, defined as the combination of cells,
scaffolding, and signaling to form a biologically active
tissue,1 offers potential alternatives to the problem of sub-
optimal bypass conduits. Save the pioneering work by
Herring that introduced the concept seeding the luminal
surface of nonabsorbable prosthetic grafts to improve pa-
tency,2 this field largely began with Weinberg and Bell’s
report of collagen tubes integrated within a Dacron mesh
and seeded with endothelial cells.3 Significant progress and
milestones have been achieved since, as outlined by multi-
ple current and excellent reviews.1,4-7 As can be imagined,
a myriad of cell and scaffold combinations have been inves-
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digms that foster graft functionality. These paradigms in-
volve altering the cell/scaffold microenvironment to
optimize luminal nonthrombogenicity, graft strength and
compliance, and vasoactivity.
The use of autologous differentiated endothelial cells
to line the lumen of a graft is hampered by the need to
harvest a blood vessel from the patient and then isolate and
culture enough endothelial cells to seed the conduit con-
fluently. Autologous stem cells derived from the recipient’s
tissues represent an alternative source of cells. To date,
most attempts to create tissue-engineered grafts with stem
cells have used either endothelial progenitor cells (EPCs)
harvested from blood, or stem cells harvested from bone
marrow.1,4-7 Both of these cell populations have shown
remarkable potential to modulate into endothelial-like
cells; however, given their origins within the bone marrow,
cell availability may be severely hampered by advanced
patient age and other comorbidities associated with vascu-
lar disease.8
In an attempt to alleviate the problem of cell availabil-
ity, we initiated efforts to isolate from subcutaneous fat a
population of cells that can differentiate into endothelial-
like cells. Autologous adipose tissue is harvested easily and
in abundance from most patients by using local anesthesia
and a small liposuction cannula. After enzymatic dispersion
of the tissue specimen, mature adipocytes are separated
from the stromal-vascular fraction by using centrifugation.
After a brief period of culture (days), during which the
adipose-derived stem cell (ASC) population adheres to the
culture dish, an abundant amount of cells with homoge-
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stem cell line, ASCs have been shown to differentiate into
multiple cell lines, including bone, fat, muscle, and carti-
lage,11 and more recently, endothelial cells12-14 and
smooth muscle cells.15
This review elucidates our work defining two critical
characteristics of human stem cells isolated from adipose
tissue: (1) availability in patient populations most likely to
benefit from this technology, and (2) potency to differenti-
ate into endothelial cells in response to in vitro microenvi-
ronmental cues. Within this framework, we emphasize the
practical nature of using these cells to create a tissue-
engineered bypass graft.
AVAILABILITY OF ADIPOSE-DERIVED STEM
CELLS
One of the most important characteristics of a cell type
used in tissue engineering is that it be readily and abun-
dantly available in the specific patient population in which it
is intended for use. In the case of small-artery bypass, the
cell must be obtainable in the elderly population with
multiple cardiovascular risk factors such as diabetes. If a
particular cell type is quite rare, ex vivo amplification be-
comes necessary before graft creation, increasing both time
Fig 1. Morphologic and molecular characterization of
micrograph (original magnification 40, unstained) of A
After negative selection of cells for CD31 and CD45 us
cell sorting of ASCs grown in culture (passage four) dem
CD29, (C) CD13, and (D) CD90 surface markers.and expense in an already costly manufacturing process.Many of the original studies evaluating fat as a source of
stem cells examined liposuction specimens obtained from
young, healthy plastic surgery patients.9,11 The applicabil-
ity of such studies in the vascular population is questionable
because it is likely that age and comorbidity adversely affect
most cell populations.
To address this issue, our group studied the availability
of ASCs in 49 patients undergoing elective vascular surgical
procedures.16 These patients each donated approximately
15 grams of periumbilical fat obtained by liposuction dur-
ing the vascular procedure. After enzymatic dispersion,
positive selection for absorbance to culture dish plastic for 1
week, and negative selection for CD31 and CD45 using
magnetic beads, a homogenous population of ASCs was
obtained. Florescence-activated cell sorting revealed these
cells to be 98% positive for CD13, CD29, and CD90 (Fig
1), cell surface antigens reported by others to be common
to ASCs.9
The number of stem cells per gram of adipose tissue
harvested was analyzed with respect to patient age, gender,
and body mass index, as well as the presence of diabetes,
end-stage renal disease, and peripheral vascular disease. The
major finding of this study was that stem cells availability
was not proven inferior for those of advanced age, obesity,
ose-derived stem cells (ASCs). A, Inverted phase light
grown in culture demonstrate spindle-like morphology.
agnetic cell sorting, representative fluorescent activated
rate a homogeneous population of cells positive for (B)adip
SCs
ing m
onstrenal failure, or vascular disease (Table). The presence of
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cells harvested, but not to a point where stem cell harvest
would be considered impractical in this patient population.
As determined from the number of cells obtained 1 week
after harvest, an average of only 50 to 100 grams of adipose
tissue would be required to seed confluently the luminal
surface of a 40-cm 6-mm bypass graft. In sum, this study
suggests that ASCs are a practical source of autologous
mesenchymal adult stem cells that can be used for tissue
engineering purposes.
POTENCY OF ADIPOSE-DERIVED STEM CELLS
The ability to acquire characteristics of cells resident
within vascular tissue represents another important aspect
of the stem cell’s usefulness in tissue engineering. Recent
evidence suggests that ASCs have the ability to transform
into cells with endothelial12-14 and smooth muscle15 phe-
notypes.
The traditional cell used to impart a nonthrombogenic
luminal surface on a vascular graft is the endothelial cell.
Hence, our group has focused on the microenvironmental
cues that might differentiate ASCs towards endothelial
cells.17 Among a host of factors, we have examined the
effects of chemical (growth factors) and physical (shear
force) stimuli on ASCs obtained from patients undergoing
elective vascular surgical procedures. In practice, the stem
cells would be exposed to the growth factors immediately
after isolation and throughout the seeding (graft creation)
process. The application of shear force could also be applied
during the seeding process, taking advantage of its ability to
promote cell attachment and retention, and would con-
tinue in vivo after graft implantation.
The specific endothelial phenotypes examined in these
experiments were (1) morphologic changes (alignment
with flow) in response to shear force and seeding (cord
formation) on Matrigel (BD Biosciences, San Jose, Calif),
and (2) expression of endothelial proteins, including endo-
thelial nitric oxide synthase (eNOS), von Willebrand factor
(vWF), and CD31. The undifferentiated stem cells in vitro
did not demonstrate any of these endothelial phenotypes.
After 3 weeks of culture in media containing endothelial
cell growth supplement (Fig 2), the ASCs realigned with
Table. Availability of adipose-derived stem cells in
patients undergoing elective vascular surgical procedures*
Patients population ASCs/g of fat P
All patients (n  49) 134,167
Age 70 years 156,350 NS
Body mass index 30 169,044 NS
Diabetic patients 87,086 .05
Renal failure 141,156 NS
PVD 148,384 NS
ACS, Adipose-derived stem cells; PVD, peripheral vascular disease; NS, not
significant
*The number of stem cells harvested did not appear to be affected by patient
age, obesity, renal failure, or PVD.shear force and formed cords in Matrigel. Expression ofeNOS, vWF, and CD31was not demonstrated by polymer-
ase chain reaction orWestern blot. However, the continued
exposure of the cells in culture to physiologic shear force
(12 dynes) did result in expression of CD31 message and
protein.
These studies, along with the noted recent literature,
suggested the potential of these stem cells to become
endothelial-like. The lack of eNOS expression raised con-
cern about the usefulness of ASCs to provide a graft with a
nonthrombogenic lumen. Indeed, a small pilot study ex-
amining the effect of seeding grafts with undifferentiated
ASCs in a canine model suggested that the cells did not
provide the conduit with a nonthrombogenic lumen.18
Vascular endothelial growth factor (VEGF) is a well-
known and important stimulus of angiogenesis and endo-
thelial progenitor cell (EPC) differentiation into endothe-
lial cells. In studies similar to those just outlined, our group
examined the effect VEGF on the differentiation of ASCs
into endothelial cells.19 After in vitro culture of the cells for
a minimum of 1 week in endothelial growth media
(EGM-2, Cambrex, East Rutherford, NJ) containing 10
g/mL VEGF and other growth factors, the ASCs again
demonstrated realignment with flow and cord formation in
Matrigel. Of greater significance was that message for
eNOS, vWF, and CD31 was detected (Fig 3). This finding
requires further confirmation with Western blotting but
suggests that these stem cells may indeed be an appropriate
cell for vascular graft creation.
ADDITIONAL STUDIES WITH ADIPOSE-
DERIVED STEM CELLS
An important aspect of designing a vascular graft is
creating a stable, nonthrombogenic luminal surface. These
preliminary data suggest that undifferentiated ASCs may
not be inherently nonthrombogenic; therefore, successful
use of these stem cells will likely require differentiation
before implantation into the vascular system. Although one
potential advantage of stem cells over differentiated endo-
thelial cells for use in graft creation lies in ease of harvest
and availability, the time required for differentiation may
offset this advantage.
One of the goals of our work using ASCs is to incor-
porate this differentiation requirement into the process of
establishing a stable monolayer of cells on the graft lumen,
thereby minimizing the time for graft creation. Herein,
taking advantage of the ASC’s responsiveness to shear, we
have begun to examine the effect of flow conditioning on
the retention of stem cells seeded onto the surface of our
scaffold of choice— decellularized vein graft.20,21 Flow
conditioning has been used by others to enhance the at-
tachment of endothelial cells to vascular grafts.22 After
seeding and culture of the grafts under static conditions for
up to 4 days, exposure of the stem cells to minimal amounts
of shear force (3 dynes for 1 hour) results in substantial loss
of cells (DiMuzio, unpublished data, 2006). In contrast,
seeded stem cells that have been gradually exposed to
increasing shear stress up to 12 dynes for 3 days remain fully
adherent and demonstrate realignment with flow (Fig 4).
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Adult autologous stem cells represent an important
source of cells for vascular tissue engineering. Their useful-
Fig 2. Differentiation of adipose-derived stem cells (ASCs
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(vWF) nor endothelial nitric oxide synthase (eNOS) was dgrowth media.ness is directly related to the availability of the cells in
patient populations with vascular diseases as well as their
ability to differentiate efficiently into vascular cells, partic-
sponse to endothelial cell growth supplement (ECGS) and
aphs (originalmagnification40, unstained) showhuman
t) and aligning in thedirectionof shear stress (arrow, right).
r a minimum of 3 weeks (lower two panels). B, Molecular
RT-PCR) detecting CD31 message in human endothelial
lls before (upper row) and after (lower row) exposure to 12
ear express CD31 message, an endothelial cell phenotype
logous to those in B, Western blot for CD31 protein
stress express CD31 at the protein level.D, Immunohis-
magnification 40) of ASCs grown in ECGS, exposed to
resence of CD31 protein within the differentiated ASCs.
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Fig 3. Differentiation of adipose-derived stem cells (ASCs)when cultured inmedia containing vascular endothelial growth
factor (VEGF). Stem cells grown inmedia containingVEGF (see text) for aminimumof 1week expressmessage for proteins
specific for endothelial cells, suggesting the ability of ASCs to differentiate towards endothelial lineage. Human endothelial
(EC) and smooth muscle (SMC) cells served as positive and negative controls, respectively. vWF, Von Willebrand factor;
eNOS, endothelial nitric oxide synthase; RT-PCR, reverse transcriptase-polymerase chain reaction; EGM2, endothelial cell
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our group and others suggests that stem cells derived from
human adipose tissue appear to possess these important
characteristics. Further work is necessary to optimize the
microenvironmental cues important for the efficient differ-
entiation of the cells and attachment onto vascular graft
scaffolds.
REFERENCES
1. Riha GM, Lin PH, Lumsden AB, Yao Q, Chen C. Application of stem
cells for vascular tissue engineering. Tissue Eng 2005;11:1535-52.
2. Herring MB, Dilley R, Jersild RA Jr, Boxer L, Gardner A, Glover J.
Seeding arterial prostheses with vascular endothelium. The nature of the
lining. Ann Surg 1979;190:84-90.
3. Weinberg CB, Bell E. A blood vessel model constructed from collagen
and cultured vascular cells. Science 1986;87:397-400.
4. Isenberg BC, Williams C, Tranquillo RT. Small-diameter artificial ar-
teries engineered in vitro. Circ Res 2006;98:25-35.
5. Barrilleaux B, Phinney DG, Prockop Darwin, O’Connor KC. Review:
Ex vivo engineering of living tissues with adult stem cells. Tissue Eng
Fig 4. Attachment and retention of adipose-derived stem cells to
vascular scaffolding. Laser confocal micrograph (original magnifi-
cation 100, phalloidin and propidium iodide stain) of human
stem cells seeded onto decellularized vein allograft. After 24 hours
of static seeding, the graft was exposed to gradually increasing
shear force (from 0 to 9 dynes) over 72 hours. The arrow indicates
direction of flow. The stem cells aligned with flow and maintained
a confluent monolayer of cells under physiological shear force.2006;12:1-13.6. Levenberg S. Engineering blood vessels from stem cells: recent advances
and application. Curr Opin Biotechnol 2005;16:516-23.
7. Sales KM, Salacinski HJ, Alobaid N, Mikhail M, Balakrishnan B, Se-
falian AM. Advancing vascular tissue engineering: the role of stem cell
technology. Trends Biotechnol 2005;9:461-7.
8. Dzau VJ, Gnecchi M, Pachori AS, Morello F, Melo LG. Therapeutic
potential of endothelial progenitor cells in cardiovascular diseases. Hy-
pertension 2005;46:7-18.
9. Katz AJ, Tholpady A, Tholpady SS, ShangH,Ogle RC. Cell surface and
transcriptional characterization of human adipose-derived adherent
stromal (hADAS) cells. Stem Cells 2005;23:412-23.
10. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et
al. Immunophenotype of human adipose-derived cells: Temporal
changes in stromal-associated and stem cell-associated markers. Stem
Cells 2006;24:376-85.
11. Zuk PA, Zhu M, Ashjian P, DeUgarte DA, Huang JI, Mizuno H, et al.
Human adipose tissue is a source of multipotent stem cells. Mol Biol
Cell 2002;12:4279-95.
12. Planat-Benard V, Silvestre J-S, Cousin B, Andre M, Nibbelink M,
Tamarat R, Clergue M, et al. Plasticity of human adipose lineage cells
toward endothelial cells: Physiological and therapeutic perspectives.
Circulation 2004;109:656-63.
13. Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie
A. Improvement of postnatal neovascularization by human adipose
tissue-derived stem cells. Circulation 2004;110:349-55.
14. Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao RC. Human adipose
tissue-derived stem cells differentiate into endothelial cells in vitro and
improve postnatal neovascularization in vivo. Biochem Biophys Res
Commun 2005;332:370-9.
15. Rodriguez LV, Alfonso Z, Zhang R, Leung J, Wu B, Ignarro LJ.
Clonogenic multipotent stem cells in human adipose tissue differentiate
into functional smoothmuscle cells. Proc Natl Acad Sci USA 2006;103:
12167-72.
16. DiMatteo CA, Golesorkhi N, Fischer LJ, Wrigley CW, McIlhenny SE,
Tulenko TN, et al. Isolation of adipose-derived stem cells in patients
with vascular disease. Circulation 2006;114(suppl II):446.
17. Fischer LJ, Lee AE, DiMatteo CA, Golesorkhi N, Wrigley CW, Galler
A, et al. Role of chemical and physical stimuli in the differentiation of
stem cells towards and endothelial phenotype. J Am Coll Surg 2006;
203(3S):S105.
18. Golesorkhi N, DiMatteo C, Grabo D, Fischer L, Tarola N, Shapiro I, et
al. In vivo study of a tissue engineered graft seeded with autologous
stem cells. Presented at the 2nd Annual Surgical Congress, Phoenix,
Ariz, Feb 6-9, 2007.
19. Mericli A, Tarola N, Fischer L, DiMatteo C, Golesorkhi N, Grabo D,
McIlhenny S, Scully K, Tulenko T, Shapiro I, DiMuzio P. Growth-
factor rich endothelilial cell media induces adipose-derived stem cells to
acquire endothelial cell phenotype. Presented at the 2nd Annual Surgi-
cal Congress, Phoenix, Ariz, Feb 6-9, 2007.
20. Schaner PJ, Martin ND, Tulenko TN, Shapiro IM, Tarola NA, Leichter
RF, et al. Decellularized vein as a potential scaffold for vascular tissue
engineering. J Vasc Surg 2004;40:146-53.
21. Martin ND, Schaner PJ, Tulenko TN, Shapiro IM, DiMatteo CA,
Williams TK, et al. In vivo behavior of decellularized vein allograft.
J Surg Res 2005;129:17-23.
22. Isenberg BC, Williams C, Tranquillo RT. Endothelialization and flow
conditioning of fibrin-based media-equivalents. Ann Biomed Eng
2006;34:971-85.Submitted Jan 18, 2007; accepted Feb 16, 2007.
